Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Medical Officer | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,059 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 9,727 · Balance 43,059 F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.11 · Expires 2030-11-12 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 01:19 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 9,727 | $2.18 | $21,204.86 |
DisclosureSEC source: 0001628280-26-064317 · wk-form4_1790889591.xml · nonDerivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,059 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 335 | $2.39 | $801.62 |
DisclosureSEC source: 0001838041-26-000004 · wk-form4_1770775846.xml · nonDerivative · entry 2 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,332 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 02:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,962 | $2.43 | $7,196.77 |
DisclosureSEC source: 0001838041-26-000004 · wk-form4_1770775846.xml · nonDerivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,667 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 01:34 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 365,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001838041-26-000002 · wk-form4_1768008888.xml · derivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 365,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 06, 2025 Filed Feb 12, 2025 22:00 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock | 20,000 | $2.28 | $45,656.00 |
DisclosureSEC source: 0001725160-25-000047 · wk-form4_1739397624.xml · nonDerivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,629 Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 16,629 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001725160-25-000037 · wk-form4_1738798229.xml · derivative · entry 2 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,629 Underlying: Common Stock · 16,629 shares Expires 2035-02-02 F2 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 16,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000037 · wk-form4_1738798229.xml · nonDerivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,629 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 712,650 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001725160-24-000190 · wk-form4_1733270555.xml · derivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,650 Underlying: Common Stock · 712,650 shares Expires 2034-12-02 F1 · derivative.exercise_date: The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 13:25 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $14.11 | $0.00 |
DisclosureSEC source: 0001104659-21-141741 · tm2133436-9_4seq1.xml · derivative · entry 1 Bruns Ingmar · CIK 0001838041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 400,000 shares Expires 2030-11-12 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.